Latest Insider Transactions at Deciphera Pharmaceuticals, Inc. (DCPH)
This section provides a real-time view of insider transactions for Deciphera Pharmaceuticals, Inc. (DCPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Deciphera Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Deciphera Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2023
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,576
+7.98%
|
-
|
|
Oct 28
2023
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,576
+10.09%
|
-
|
|
Oct 28
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,244
+8.14%
|
-
|
|
Oct 28
2023
|
Steven L. Hoerter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+50.0%
|
-
|
|
Oct 28
2023
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,244
+11.2%
|
-
|
|
Oct 02
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,942
-3.36%
|
$35,304
$12.68 P/Share
|
|
Sep 15
2023
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,900
+42.37%
|
-
|
|
Jun 16
2023
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,655
-2.81%
|
$23,170
$14.4 P/Share
|
|
Jun 16
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,238
-2.08%
|
$17,332
$14.4 P/Share
|
|
Jun 16
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,655
-2.81%
|
$23,170
$14.4 P/Share
|
|
Jun 16
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,655
-1.85%
|
$23,170
$14.4 P/Share
|
|
Jun 16
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,238
-2.75%
|
$17,332
$14.4 P/Share
|
|
Jun 08
2023
|
Franklin Stuart Friedman |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$130,000
$13.88 P/Share
|
|
May 10
2023
|
Dennis Leo Walsh |
BUY
Open market or private purchase
|
Direct |
11,000
+50.0%
|
$143,000
$13.86 P/Share
|
|
Mar 21
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$112,500
$15.57 P/Share
|
|
Feb 28
2023
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
2,427,693
+9.88%
|
$0
$0.01 P/Share
|
|
Feb 16
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,159
-2.51%
|
$17,385
$15.1 P/Share
|
|
Feb 16
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,370
-2.28%
|
$20,550
$15.1 P/Share
|
|
Feb 16
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,159
-1.95%
|
$17,385
$15.1 P/Share
|
|
Feb 16
2023
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,370
-2.28%
|
$20,550
$15.1 P/Share
|
|
Feb 16
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
971
-1.09%
|
$14,565
$15.1 P/Share
|
|
Feb 15
2023
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,151
+19.44%
|
-
|
|
Feb 15
2023
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,488
+21.51%
|
-
|
|
Feb 15
2023
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,151
+15.77%
|
-
|
|
Feb 15
2023
|
Daniel Lee Flynn Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,488
+21.5%
|
-
|
|
Feb 15
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,488
+15.61%
|
-
|
|
Feb 14
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
30,045
-80.02%
|
$480,720
$16.0 P/Share
|
|
Jan 24
2023
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,666,666
+7.79%
|
$29,999,988
$18.0 P/Share
|
|
Jan 17
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,403
-5.21%
|
$50,463
$21.24 P/Share
|
|
Jan 17
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,603
-3.21%
|
$33,663
$21.24 P/Share
|
|
Jan 17
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,403
-3.2%
|
$50,463
$21.24 P/Share
|
|
Jan 17
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,603
-4.37%
|
$33,663
$21.24 P/Share
|
|
Jan 17
2023
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,403
-5.21%
|
$50,463
$21.24 P/Share
|
|
Oct 03
2022
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,587
-3.36%
|
$46,566
$18.73 P/Share
|
|
Jun 16
2022
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,768
-3.69%
|
$17,680
$10.75 P/Share
|
|
Jun 16
2022
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,768
-3.7%
|
$17,680
$10.75 P/Share
|
|
Jun 16
2022
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,311
-2.58%
|
$13,110
$10.75 P/Share
|
|
Jun 16
2022
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,298
-3.42%
|
$12,980
$10.75 P/Share
|
|
Jun 16
2022
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,768
-2.25%
|
$17,680
$10.75 P/Share
|
|
Apr 29
2022
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,478,978
+7.57%
|
$14,789,780
$10.0 P/Share
|
|
Mar 21
2022
|
Steven L. Hoerter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,150
-7.74%
|
$28,350
$9.11 P/Share
|
|
Feb 16
2022
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,146
-2.93%
|
$10,314
$9.05 P/Share
|
|
Feb 16
2022
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,368
-2.78%
|
$12,312
$9.05 P/Share
|
|
Feb 16
2022
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
984
-1.27%
|
$8,856
$9.05 P/Share
|
|
Feb 16
2022
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,146
-2.3%
|
$10,314
$9.05 P/Share
|
|
Feb 16
2022
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,366
-2.77%
|
$12,294
$9.05 P/Share
|
|
Jan 18
2022
|
Daniel Lee Flynn Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+29.4%
|
-
|
|
Jan 18
2022
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,667
+25.9%
|
-
|
|
Jan 18
2022
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+20.86%
|
-
|
|
Jan 18
2022
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,667
+21.53%
|
-
|